Discover and develop innovative cancer therapies, focusing on immuno-oncology and targeted treatments. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 46% a year over the last 4 years. Red columns mark years that ended in a loss.
The market pays 129× for every dollar this company earns in a year — a price that already assumes things go well.
Against companies in its own sector, it looks cheaper than 44% of them.
Analysts' average target sits 16% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
Clearly below the class average.
The stock has been running stronger than the market lately.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades below its recent peak — about 11% off the top. A pullback, not a collapse.
Over the last 4 years, sales grew about 46% a year on average.
There is $4.5B in the vault; even if every debt were paid off, $2.5B would remain.
The company’s market value is 129 times its annual profit. Even a small disappointment could hit the price hard.
Over the last 12 months, executives reported 243 sells against just 79 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, ONC sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ONC is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (44/100) says the stock isn’t cheap.